Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
J Clin Oncol
    April 2024

  1. Erratum: Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study.
    J Clin Oncol. 2024 Apr 16:JCO2400454. doi: 10.1200/JCO.24.00454.
    >> Share

    March 2024
  2. YU JB, DeStephano DM, Jeffers B, Horowitz DP, et al
    Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer.
    J Clin Oncol. 2024 Mar 20:JCO2301604. doi: 10.1200/JCO.23.01604.
    >> Share

  3. MADAN RA, Yu EY, Posadas EM, Lee RJ, et al
    Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care.
    J Clin Oncol. 2024 Mar 15:JCO2302727. doi: 10.1200/JCO.23.02727.
    >> Share

  4. FALLAH J, Xu J, Weinstock C, Gao X, et al
    Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
    J Clin Oncol. 2024 Mar 14:JCO2302105. doi: 10.1200/JCO.23.02105.
    >> Share

  5. KWAK L, Ravi P, Armstrong JG, Beckendorf V, et al
    Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials.
    J Clin Oncol. 2024 Mar 12:JCO2300762. doi: 10.1200/JCO.23.00762.
    >> Share

  6. HEISS BL, Chang E, Gao X, Truong T, et al
    US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2024 Mar 7:JCO2302182. doi: 10.1200/JCO.23.02182.
    >> Share

    January 2024
  7. AGGARWAL R, Heller G, Hillman DW, Xiao H, et al
    PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
    J Clin Oncol. 2024 Jan 23:JCO2301157. doi: 10.1200/JCO.23.01157.
    >> Share

  8. CHILDS DS, Orme JJ, Ravi P
    Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent Prostate Cancer: Is It Clinically Meaningful?
    J Clin Oncol. 2024 Jan 23:JCO2302410. doi: 10.1200/JCO.23.02410.
    >> Share

  9. HALABI S, Roy A, Rydzewska L, Guo S, et al
    Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2024 Jan 5:JCO2301535. doi: 10.1200/JCO.23.01535.
    >> Share

  10. DENMEADE SR
    Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen-Based Therapies for Prostate Cancer.
    J Clin Oncol. 2024 Jan 5:JCO2302310. doi: 10.1200/JCO.23.02310.
    >> Share

    December 2023
  11. FALLAH J, Xu J, Weinstock C, Brave MH, et al
    FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2023 Dec 21:JCO2301868. doi: 10.1200/JCO.23.01868.
    >> Share

    November 2023
  12. MATEO J, de Bono JS, Fizazi K, Saad F, et al
    Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
    J Clin Oncol. 2023 Nov 14:JCO2300339. doi: 10.1200/JCO.23.00339.
    >> Share

  13. ROY S, Romero T, Michalski JM, Feng FY, et al
    Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.
    J Clin Oncol. 2023;41:5005-5014.
    >> Share

  14. GARJE R, Rumble RB, Parikh RA
    Systemic Therapy Update on (177)Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2023 Nov 6:JCO2302128. doi: 10.1200/JCO.23.02128.
    >> Share

  15. TAGAWA ST, Thomas C, Sartor AO, Sun M, et al
    Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of (225)Ac-J591.
    J Clin Oncol. 2023 Nov 3:JCO2300573. doi: 10.1200/JCO.23.00573.
    >> Share

    October 2023
  16. GONG J, Kim DM, De Hoedt AM, Bhowmick N, et al
    Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?
    J Clin Oncol. 2023 Oct 27:JCO2300949. doi: 10.1200/JCO.23.00949.
    >> Share

  17. MADAN RA, Karzai F, VanderWeele DJ, Cheng HH, et al
    Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits.
    J Clin Oncol. 2023 Oct 17:JCO2301502. doi: 10.1200/JCO.23.01502.
    >> Share

    September 2023
  18. FRANCOLINI G, Gaetano Allegra A, Detti B, Di Cataldo V, et al
    Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO).
    J Clin Oncol. 2023 Sep 21:JCO2300985. doi: 10.1200/JCO.23.00985.
    >> Share

  19. STAR J, Bandi P, Siegel RL, Han X, et al
    Cancer Screening in the United States During the Second Year of the COVID-19 Pandemic.
    J Clin Oncol. 2023;41:4352-4359.
    >> Share

    August 2023
  20. SLOVIN SF, Knudsen K, Halabi S, de Leeuw R, et al
    Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2023 Aug 15:JCO2202639. doi: 10.1200/JCO.22.02639.
    >> Share

  21. MAI Z, Yan W, Zhou Y
    Several Questions About Prostate-Specific Antigen and Salvage Radiotherapy After Radical Prostatectomy.
    J Clin Oncol. 2023;41:3956.
    >> Share

    July 2023
  22. DAI C, Dehm SM, Sharifi N
    Targeting the Androgen Signaling Axis in Prostate Cancer.
    J Clin Oncol. 2023 Jul 10:JCO2300433. doi: 10.1200/JCO.23.00433.
    >> Share

  23. STOPSACK KH, Mucci LA, Giovannucci EL
    Aggressive Prostate Cancer Is Preventable and so Are Racial Disparities.
    J Clin Oncol. 2023 Jul 10:JCO2300507. doi: 10.1200/JCO.23.00507.
    >> Share

  24. ROACH M 3RD, Chapman C, Coleman PW
    Racism Might Cause Prostate Cancer and Definitely Causes Excess Unemployment, Lost Wages, and Excess Cancer Deaths.
    J Clin Oncol. 2023 Jul 10:JCO2300502. doi: 10.1200/JCO.23.00502.
    >> Share

    June 2023
  25. MICHALSKI JM, Winter KA, Prestidge BR, Sanda MG, et al
    Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.
    J Clin Oncol. 2023 Jun 14:JCO2201856. doi: 10.1200/JCO.22.01856.
    >> Share

  26. ANTONARAKIS ES, Park SH, Goh JC, Shin SJ, et al
    Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
    J Clin Oncol. 2023 Jun 8:JCO2300233. doi: 10.1200/JCO.23.00233.
    >> Share

  27. WALA J, Nguyen P, Pomerantz M
    Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2023 Jun 2:JCO2300723. doi: 10.1200/JCO.23.00723.
    >> Share

    May 2023
  28. HINDIE E
    Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2023 May 31:JCO2300686. doi: 10.1200/JCO.23.00686.
    >> Share

  29. ABNER A, Vicini F
    Regarding Sequencing of Androgen-Deprivation Therapy.
    J Clin Oncol. 2023;41:2448-2449.
    >> Share

    April 2023
  30. KRAUSS DJ, Karrison T, Martinez AA, Morton G, et al
    Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.
    J Clin Oncol. 2023 Apr 27:JCO2202390. doi: 10.1200/JCO.22.02390.
    >> Share

  31. MOVSAS B, Rodgers JP, Elshaikh MA, Martinez AA, et al
    Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial.
    J Clin Oncol. 2023 Apr 27:JCO2202389. doi: 10.1200/JCO.22.02389.
    >> Share

  32. MARSHALL CH
    Acting on Actionable Mutations in Metastatic Prostate Cancer.
    J Clin Oncol. 2023 Apr 25:JCO2300350. doi: 10.1200/JCO.23.00350.
    >> Share

  33. HALABI S, Yang Q, Roy A, Luo B, et al
    External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2023 Apr 11:JCO2202661. doi: 10.1200/JCO.22.02661.
    >> Share

  34. DORFF T, Tripathi A
    Incorporating Prognostic Models Into Clinical Practice for Patients With Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2023 Apr 11:JCO2300374. doi: 10.1200/JCO.23.00374.
    >> Share

  35. VIRGO KS, Rumble RB, Talcott J
    Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update.
    J Clin Oncol. 2023 Apr 3:JCO2300155. doi: 10.1200/JCO.23.00155.
    >> Share

    March 2023
  36. MORRIS MJ, Heller G, Hillman DW, Bobek O, et al
    Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
    J Clin Oncol. 2023 Mar 30:JCO2202394. doi: 10.1200/JCO.22.02394.
    >> Share

  37. ANTONARAKIS ES, Abida W
    Combining Poly(ADP)-Ribose Polymerase Inhibitors With Abiraterone in Castration-Resistant Prostate Cancer: Is Biomarker Testing Necessary?
    J Clin Oncol. 2023 Mar 23:JCO2300270. doi: 10.1200/JCO.23.00270.
    >> Share

  38. CHI KN, Rathkopf D, Smith MR, Efstathiou E, et al
    Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2023 Mar 23:JCO2201649. doi: 10.1200/JCO.22.01649.
    >> Share

  39. MCMANUS HD, Armstrong AJ
    The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2023 Mar 22:JCO2300323. doi: 10.1200/JCO.23.00323.
    >> Share

  40. TILKI D, Chen MH, Wu J, Huland H, et al
    Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death.
    J Clin Oncol. 2023 Mar 1:JCO2202489. doi: 10.1200/JCO.22.02489.
    >> Share

    February 2023
  41. HUSSAIN M, Tombal B, Saad F, Fizazi K, et al
    Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
    J Clin Oncol. 2023 Feb 16:JCO2300041. doi: 10.1200/JCO.23.00041.
    >> Share

  42. GILLESSEN S, Procopio G, Hayoz S, Kremer E, et al
    Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).
    J Clin Oncol. 2023 Feb 8:JCO2201726. doi: 10.1200/JCO.22.01726.
    >> Share

    January 2023
  43. VICKERS AJ, Mahal B, Ogunwobi OO
    Racism Does Not Cause Prostate Cancer, It Causes Prostate Cancer Death.
    J Clin Oncol. 2023 Jan 24:JCO2202203. doi: 10.1200/JCO.22.02203.
    >> Share

    December 2022
  44. NYBERG T, Brook MN, Ficorella L, Lee A, et al
    CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer.
    J Clin Oncol. 2022 Dec 9:JCO2201453. doi: 10.1200/JCO.22.01453.
    >> Share

  45. BABOUDJIAN M, Roupret M, Ploussard G
    Redefining Gleason 6 Prostate Cancer Nomenclature: The Surgeon's Perspective.
    J Clin Oncol. 2022 Dec 2:JCO2201621. doi: 10.1200/JCO.22.01621.
    >> Share

    November 2022
  46. TRAN PT, Lowe K, Tsai HL, Song DY, et al
    Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
    J Clin Oncol. 2022 Nov 11:JCO2201662. doi: 10.1200/JCO.22.01662.
    >> Share

    October 2022
  47. MA TM, Sun Y, Malone S, Roach M 3rd, et al
    Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.
    J Clin Oncol. 2022 Oct 21:JCO2200970. doi: 10.1200/JCO.22.00970.
    >> Share

  48. KIM JW, McKay RR, Radke MR, Zhao S, et al
    Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
    J Clin Oncol. 2022 Oct 18:JCO2102947. doi: 10.1200/JCO.21.02947.
    >> Share

    September 2022
  49. EPSTEIN JI, Kibel AS
    Renaming Gleason Score 6 Prostate to Noncancer: A Flawed Idea Scientifically and for Patient Care.
    J Clin Oncol. 2022;40:3106-3109.
    >> Share

  50. GARJE R, Rumble RB, Parikh RA
    Systemic Therapy Update on (177)Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation.
    J Clin Oncol. 2022 Sep 16:JCO2201865. doi: 10.1200/JCO.22.01865.
    >> Share

    August 2022
  51. DEEK MP, Van der Eecken K, Sutera P, Deek RA, et al
    Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.
    J Clin Oncol. 2022 Aug 24:JCO2200644. doi: 10.1200/JCO.22.00644.
    >> Share

  52. SUN R, Wei LJ
    Quantifying Clinical Utility of Enzalutamide for Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2022 Aug 19:JCO2201084. doi: 10.1200/JCO.22.01084.
    >> Share

    July 2022
  53. TISSEVERASINGHE S, Tolba M, Saad F, Gravis G, et al
    Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?
    J Clin Oncol. 2022 Jul 21:JCO2200883. doi: 10.1200/JCO.22.00883.
    >> Share

    June 2022
  54. JACKSON WC, Tang M, Schipper MJ, Sandler HM, et al
    Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.
    J Clin Oncol. 2022 Jun 23:JCO2102741. doi: 10.1200/JCO.21.02741.
    >> Share

  55. KARTOLO A, Tannock IF, Vera Badillo FE
    Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
    J Clin Oncol. 2022 Jun 20:JCO2200705. doi: 10.1200/JCO.22.00705.
    >> Share

  56. MADAN RA, Mena E, Lindenberg L, Choyke PL, et al
    With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer.
    J Clin Oncol. 2022 Jun 3:JCO2200493. doi: 10.1200/JCO.22.00493.
    >> Share

  57. BROOKS GA, Landrum MB, Kapadia NS, Liu PH, et al
    Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment.
    J Clin Oncol. 2022;40:1763-1771.
    >> Share

    May 2022
  58. CAO Y, Deville C Jr
    Adjuvant Radiation for Pathologically Node-Positive Prostate Cancer: Evidence When Early Salvage May Not Be Early Enough.
    J Clin Oncol. 2022 May 23:JCO2200645. doi: 10.1200/JCO.22.00645.
    >> Share

    April 2022
  59. AGARWAL N, Tangen CM, Hussain MHA, Gupta S, et al
    Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
    J Clin Oncol. 2022 Apr 21:JCO2102517. doi: 10.1200/JCO.21.02517.
    >> Share

  60. HUSSAIN M, Carducci MA, Clarke N, Fenton SE, et al
    Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?
    J Clin Oncol. 2022 Apr 19:JCO2200208. doi: 10.1200/JCO.22.00208.
    >> Share

  61. EGGENER SE, Berlin A, Vickers AJ, Paner GP, et al
    Low-Grade Prostate Cancer: Time to Stop Calling It Cancer.
    J Clin Oncol. 2022 Apr 18:JCO2200123. doi: 10.1200/JCO.22.00123.
    >> Share

  62. ARMSTRONG AJ, Azad AA, Iguchi T, Szmulewitz RZ, et al
    Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2022 Apr 14:JCO2200193. doi: 10.1200/JCO.22.00193.
    >> Share

    March 2022
  63. TILKI D, Chen MH, Wu J, Huland H, et al
    Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death.
    J Clin Oncol. 2022 Mar 15:JCO2102800. doi: 10.1200/JCO.21.02800.
    >> Share

    February 2022
  64. PATEL NA, Reiter RE
    Impact of a Novel Molecular Imaging Modality, Prostate-Specific Membrane Antigen Positron Emission Tomography, on the Management of Prostate Cancer.
    J Clin Oncol. 2022 Feb 24:JCO2102940. doi: 10.1200/JCO.21.02940.
    >> Share

  65. VAN WAMBEKE S, Vera-Badillo FE, Gyawali B
    Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?
    J Clin Oncol. 2022 Feb 21:JCO2102304. doi: 10.1200/JCO.21.02304.
    >> Share

    January 2022
  66. SCHODER H, Hope TA, Knopp M, Kelly WK, et al
    Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups.
    J Clin Oncol. 2022 Jan 11:JCO2102440. doi: 10.1200/JCO.21.02440.
    >> Share

  67. MORGANS AK, Beltran H
    Isn't Androgen Deprivation Enough? Optimal Treatment for Newly Diagnosed Metastatic Prostate Cancer.
    J Clin Oncol. 2022 Jan 6:JCO2102530. doi: 10.1200/JCO.21.02530.
    >> Share

  68. DZIMITROWICZ HE, Armstrong AJ
    Elevating the Patient Voice in Metastatic Hormone-Sensitive Prostate Cancer Clinical Trials.
    J Clin Oncol. 2022 Jan 6:JCO2102504. doi: 10.1200/JCO.21.02504.
    >> Share

    December 2021
  69. STOCKLER MR, Martin AJ, Davis ID, Dhillon HM, et al
    Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.
    J Clin Oncol. 2021 Dec 20:JCO2100941. doi: 10.1200/JCO.21.00941.
    >> Share

    November 2021
  70. RUSH HL, Murphy L, Morgans AK, Clarke NW, et al
    Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
    J Clin Oncol. 2021 Nov 10:JCO2100728. doi: 10.1200/JCO.21.00728.
    >> Share

  71. SADA YH
    A Dozen Eggs.
    J Clin Oncol. 2021;39:3645-3646.
    >> Share

    September 2021
  72. KERKMEIJER LGW, Pos FJ, Haustermans K, van der Heide UA, et al
    Reply to I. R. Vogelius et al.
    J Clin Oncol. 2021;39:3086-3087.
    >> Share

    July 2021
  73. BOLLA M, Neven A, Maingon P, Carrie C, et al
    Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease.
    J Clin Oncol. 2021 Jul 26:JCO2100855. doi: 10.1200/JCO.21.00855.
    >> Share

  74. SPERGER JM, Emamekhoo H, McKay RR, Stahlfeld CN, et al
    Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.
    J Clin Oncol. 2021 Jul 1:JCO2100169. doi: 10.1200/JCO.21.00169.
    >> Share

  75. D'AMICO AV, Xie W, McMahon E, Loffredo M, et al
    Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial.
    J Clin Oncol. 2021 Jul 1:JCO2100596. doi: 10.1200/JCO.21.00596.
    >> Share

    June 2021
  76. VOGELIUS IR, Bentzen SM
    Radiation Dose Escalation for Early Prostate Cancer: Reigniting the FLAME?
    J Clin Oncol. 2021 Jun 4:JCO2100586. doi: 10.1200/JCO.21.00586.
    >> Share

  77. YANG DD, Nguyen PL, D'Amico AV
    Elective Pelvic Lymph Node Radiation in Prostate Cancer Revisited.
    J Clin Oncol. 2021 Jun 4:JCO2100621. doi: 10.1200/JCO.21.00621.
    >> Share

  78. BRENNEMAN RJ, Baumann BC, Gay HA, Michalski JM, et al
    Regarding the Use of PSMA PET-CT Versus Conventional Imaging for Assessing the Value of Prophylactic Whole-Pelvis Radiation for High-Risk Prostate Cancer.
    J Clin Oncol. 2021 Jun 4:JCO2100634. doi: 10.1200/JCO.21.00634.
    >> Share

  79. DESS RT, Jackson WC, Spratt DE
    End Point Definitions and Surrogacy in Prostate Cancer: Will Metastasis-Free Survival Become Event-Free Survival With Advances in Molecular Imaging?
    J Clin Oncol. 2021 Jun 4:JCO2100376. doi: 10.1200/JCO.21.00376.
    >> Share

  80. TILKI D, Chen MH, Wu J, Huland H, et al
    Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death.
    J Clin Oncol. 2021 Jun 4:JCO2003714. doi: 10.1200/JCO.20.03714.
    >> Share

    May 2021
  81. TEWARI AK, Gillessen S, Sweeney CJ
    Metastatic Prostate Cancer: In Search of More Granularity.
    J Clin Oncol. 2021 May 14:JCO2100643. doi: 10.1200/JCO.21.00643.
    >> Share

    April 2021
  82. HOCHT S, Mason M, Wiegel T
    Timing of ADT in Radiotherapy of Prostate Cancer.
    J Clin Oncol. 2021 Apr 29:JCO2100032. doi: 10.1200/JCO.21.00032.
    >> Share

  83. CHI KN, Chowdhury S, Bjartell A, Chung BH, et al
    Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
    J Clin Oncol. 2021 Apr 29:JCO2003488. doi: 10.1200/JCO.20.03488.
    >> Share

  84. MURPHY AB, Abern MR, Liu L, Wang H, et al
    Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial.
    J Clin Oncol. 2021 Apr 9:JCO2002997. doi: 10.1200/JCO.20.02997.
    >> Share

    January 2021
  85. SPRATT DE, Malone S, Roy S, Grimes S, et al
    Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.
    J Clin Oncol. 2021;39:136-144.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016